Lonza Unveils Rapid Media Prototyping Service (RaMP) to Accelerate Early Biopharmaceutical Development

Lonza Switzerland

Overview

Lonza launched its Rapid Media Prototyping Service (RaMP), offering biopharmaceutical companies swift access to customized liquid and powder media for accelerated early development. This service provides non-GMP batches from 1 kg to 10 kg powder and 1 liter to 100 liters liquid within 10 working days, streamlining screening, process confirmation, and aligning early formulation work with future GMP requirements. RaMP aims to significantly reduce lead times and support a more efficient pathway to commercialization for novel biotherapeutics.

In Depth

Key Findings

Lonza has introduced an innovative service, the Rapid Media Prototyping Service (RaMP), designed to dramatically accelerate early bioprocess development for biopharmaceutical companies. This service aims to significantly reduce lead times for screening, process confirmation, and early-stage development by providing rapid access to customized liquid and powder media.

Technical and Clinical Details

The RaMP service is characterized by its ability to quickly manufacture and supply essential media to clients. Specifically, it can deliver non-GMP batches ranging from 1 kg to 10 kg of powder and 1 liter to 100 liters of liquid within a short timeframe of 10 working days. This rapid prototyping capability enables much more efficient testing and optimization of diverse media formulations in early development compared to conventional processes. It is crucial for swiftly identifying optimal media compositions that maximize cell growth and productivity of biopharmaceutical candidates. Furthermore, the service is designed to ensure that early formulation work is aligned with future Good Manufacturing Practice (GMP) requirements, supporting a seamless transition towards commercialization.

Background and Industry Context

Biopharmaceutical development often faces bottlenecks due to the complex nature of cell culture processes and media optimization, leading to prolonged development timelines and higher costs. The increasing diversification and personalization of therapeutics have amplified the need for customized media tailored to specific cell lines and manufacturing processes. Lonza’s RaMP service addresses these industry demands, contributing to faster timelines from drug discovery to market by enabling flexibility and rapid decision-making in the early development phase. This initiative has garnered attention from global pharmaceutical media, highlighting its potential to enhance global development efficiency.

Future Outlook

Rapid media prototyping services like RaMP are set to expand the frontiers of biopharmaceutical development, enabling faster patient access, particularly for orphan diseases and advanced cell and gene therapy products. In the future, integration with AI and machine learning-driven media design tools could further accelerate the development of personalized media. This service represents a significant strategic step for Lonza as a leader in the CDMO industry, supporting client innovation and driving the growth of the overall biopharmaceutical market. Efficient media supply will positively impact the entire value chain, from process development to clinical trials and commercial production, ultimately contributing to delivering more innovative therapies to the market.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime